Kura Oncology, Inc. (KURA)

NASDAQ: KURA · IEX Real-Time Price · USD
19.48
-0.92 (-4.51%)
At close: Apr 12, 2024, 4:00 PM
19.87
+0.39 (2.00%)
After-hours: Apr 12, 2024, 5:29 PM EDT
-4.51%
Market Cap 1.48B
Revenue (ttm) n/a
Net Income (ttm) -152.63M
Shares Out 76.14M
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 619,533
Open 20.30
Previous Close 20.40
Day's Range 19.00 - 20.40
52-Week Range 7.41 - 24.17
Beta 0.87
Analysts Strong Buy
Price Target 28.05 (+43.99%)
Earnings Date May 8, 2024

About KURA

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpeli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 142
Stock Exchange NASDAQ
Ticker Symbol KURA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price forecast is $28.05, which is an increase of 43.99% from the latest price.

Price Target
$28.05
(43.99% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kura Oncology to Participate in Stifel Targeted Oncology Forum

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

4 days ago - GlobeNewsWire

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines f...

9 days ago - GlobeNewsWire

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter –

5 weeks ago - GlobeNewsWire

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome –

6 weeks ago - GlobeNewsWire

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML –

6 weeks ago - GlobeNewsWire

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

7 weeks ago - GlobeNewsWire

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

7 weeks ago - GlobeNewsWire

Kura Oncology stock jumped another 20% on Tuesday: here's why

Kura Oncology Inc (NASDAQ: KURA) rallied close to 20% this morning after reporting positive preliminary data for a Phase 1 study of its Ziftomenib “in combination with standards of care”. Ziftomenib t...

2 months ago - Invezz

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80% of ...

2 months ago - GlobeNewsWire

Kura Oncology Announces Oversubscribed $150 Million Private Placement

– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents and investments expected to provide runway in...

2 months ago - GlobeNewsWire

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

4 months ago - GlobeNewsWire

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

4 months ago - GlobeNewsWire

Kura Oncology Reports Third Quarter 2023 Financial Results

– Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary data from 20 patients in KOMET-007 combination trial of ziftom...

5 months ago - GlobeNewsWire

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 – – Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) ...

5 months ago - GlobeNewsWire

Kura Oncology to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

5 months ago - GlobeNewsWire

Kura Oncology to Report Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

6 months ago - GlobeNewsWire

Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

– Phase 1 dose-escalation study to evaluate KO-2806 as a monotherapy and in combination with targeted therapies in KRASG12C-mutant NSCLC and ccRCC –

6 months ago - GlobeNewsWire

Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC

– Meaningful antitumor activity observed in recurrent/metastatic HRAS mutant HNSCC, including CR – – Data validate activity of farnesyltransferase inhibitors and support rapid advancement of KO-2806 i...

6 months ago - GlobeNewsWire

Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12 D inhibitors –

6 months ago - GlobeNewsWire

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer

– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors –

7 months ago - GlobeNewsWire

Kura Oncology to Participate in Cantor Global Healthcare Conference 2023

SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

7 months ago - GlobeNewsWire

Life Science Cares Announces Impact Level Partnership with Kura Oncology

CAMBRIDGE, Mass. & SAN DIEGO--(BUSINESS WIRE)--Life Science Cares (LSC) is thrilled to announce a new $250,000 partnership with Kura Oncology to provide additional grant funding for educational initia...

7 months ago - Business Wire

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...

8 months ago - GlobeNewsWire

Kura Oncology Reports Second Quarter 2023 Financial Results

– Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-re...

9 months ago - GlobeNewsWire

Kura Oncology to Report Second Quarter 2023 Financial Results

SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...

9 months ago - GlobeNewsWire